BioCatalystWatch
SDGRWorkspace / SDGR / OverviewCompany library
Price
Market cap
Next catalystDec 12-15, 2026SGR-1505 · Phase 1 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

aleniglipron

Small molecule

GLP-1 receptor

PreINDP1P2P3FilingApproved
zasocitinib

TYK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

SGR-3515

WEE1 × Myt1 (PKMYT1)

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

zasocitinib

TYK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

aleniglipron

Small molecule

GLP-1 receptor

PreINDP1P2P3FilingApproved
SGR-3515

WEE1 × Myt1 (PKMYT1)

PreINDP1P2P3FilingApproved

Other pipelines

SGR-4594

PreINDP1P2P3FilingApproved
SGR-6016

NLRP3

PreINDP1P2P3FilingApproved
SGR-3907

NLRP3

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
SGR-5573

EGFR C797S / resistant EGFR variants

PreINDP1P2P3FilingApproved
SGR-4174

SOS1

PreINDP1P2P3FilingApproved
SGR-4281

MALT1

PreINDP1P2P3FilingApproved
SGR-8139

PreINDP1P2P3FilingApproved
SGR-2290

PreINDP1P2P3FilingApproved
SGR-1820

PreINDP1P2P3FilingApproved

Partner / License out

aleniglipron

Small molecule

GLP-1 receptor

PreINDP1P2P3FilingApproved

Small molecule

Amylin receptor

PreINDP1P2P3FilingApproved

Small molecule

α4β7 integrin

PreINDP1P2P3FilingApproved

History / paused

CDC7

PreINDP1P2P3FilingApproved

CDC7

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status
6M

Market Reaction / Supply Context

Market Structure

SDGR PR & News

PR & News

SDGR SEC archive